Background: Uncontrolled immune responses in the nervous system are potentially damaging following Japanese encephalitis virus (JEV) infection. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) act together to control the proteolysis of extracellular matrix. Disbalances in the MMP/TIMP system during virally induced neurodegenerative processes and inflammations are responsive to changes in the progression of diseases. Methods: The expression of MMP-2, MMP-7, MMP-9, TIMP-1, and TIMP-3 in JEV-infected mouse brain was analyzed by RT-PCR for semiquantitation and ELISA for estimation of protein along with brain histopathology at different days postinoculation (dpi). Gelatin gel zymography was performed for MMP-2 and MMP-9 activities. Results: In the virus-infected group, expression of MMP-2, MMP-7, MMP-9, TIMP-1, and TIMP-3 was found to be increased from 1 dpi to 6 dpi as compared to controls by both RT-PCR and ELISA. The expressions of MMPs and TIMPs at mRNA and protein levels were in concordance with each other. Post hoc multiple comparison analysis between days revealed that, in the virus-infected groups, significant increases (p < 0.05) in MMP and TIMP levels were observed between various dpi at both mRNA and protein levels. Only the MMP-7 protein level at 6 dpi was not significant compared to 5 dpi (p = 0.99). Conclusion: Overexpression of MMPs and TIMPs is associated with disease severity in the central nervous system (CNS) during JEV infection. Our results showed that JEV infection can alter the expression of MMPs and TIMPs in the CNS. Thus, assessing these important immune mediators in CNS infection appears to play an important role in the development of symptoms and may help to understand the JEV-induced neurological disorders. More studies are required on this important enzymatic system to study their role in immune mediated pathogenesis.

1.
Chen CJ, Raung SL, Kuo MD, Wang YM: Suppression of Japanese encephalitis virus infection by non-steroidal anti-inflammatory drugs. J Gen Virol 2002;83:1897–1905.
2.
World Health Organization: Manual for the laboratory diagnosis of japanese encephalitis virus infection. Geneva, WHO, 2007.
3.
Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT: Japanese encephalitis. J Neurol, Neurosurg, Psychiatry 2000;68:405–415.
4.
King NJ, Shrestha B, Kesson AM: Immune modulation by flaviviruses. Adv Virus Res 2003;60:121–155.
5.
Mathur A, Arora KL, Chaturvedi UC: Host defence mechanisms against Japanese encephalitis virus infection in mice. J Gen Virol 1983;64:805–811.
6.
Desai A, Ravi V, Chandramuki A, Gourie-Devi M: Detection of neutralizing antibodies to Japanese encephalitis virus in the cerebrospinal fluid using a rapid microneutralization test. Serodiagn Immunother Infect Dis 1994;6:130–134.
7.
Murali-Krishna K, Ravi V, Manjunath R: Protection of adult but not newborn mice against lethal intracerebral challenge with Japanese encephalitis virus by adoptively transferred virus-specific cytotoxic T lymphocytes: requirement for L3T4+ T cells. J Gen Virol 1996;77:705–714.
8.
Ramakrishna C, Ravi V, Desai A, Subbakrishna DK, Shankar SK, Chandramuki A: T helper responses to Japanese encephalitis virus infection are dependent on the route of inoculation and the strain of mouse used. J Gen Virol 2003;84:1559–1567.
9.
Kumar P, Sulochana P, Nirmala G, Haridattatreya M, Satchidanandam V: Conserved amino acids 193–324 of non-structural protein 3 are a dominant source of peptide determinants for CD4+ and CD8+ T cells in a healthy Japanese encephalitis virus-endemic cohort. J Gen Virol 2004;85:1131–1143.
10.
Parks WC, Wilson CL, López-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617–629.
11.
Kieseier BC, Paul R, Koedel U, Seifert T, Clements JM, Gearing AJ, Pfister HW, Hartung HP: Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 1999;122:1579–1587.
12.
Perry VH, Anthony DC, Bolton SJ, Brown HC: The blood-brain barrier and the inflammatory response. Mol Med Today 1997;3:335–341.
13.
Ransohoff RM, Kivisäkk P, Kidd G: Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003;3:569–581.
14.
Yong VW, Power C, Forsyth P, Edwards DR: Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:502–511.
15.
Nygårdas PT, Hinkkanen AE: Up regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin Exp Immunol 2002;128:245–254.
16.
Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL: Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 1998;152:729–741.
17.
Giraudon P, Buart S, Bernard A, Thomasset N, Belin MF: Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Prog Neurobiol 1996;49:169–184.
18.
Giraudon P, Vernant JC, Confavreux C, Belin MF, Desgranges C: Matrix metalloproteinase 9 (gelatinase B) in cerebrospinal fluid of HTLV-1 infected patients with tropical spastic paraparesis. Neurology 1998;50:1920.
19.
Lezin A, Buart S, Smadja D, Akaoka H, Bourdonne O, Perret-Liaudet A, Cesaire R, Belin MF, Giraudon P: Tissue inhibitor of metalloproteinase 3, matrix metalloproteinase 9, and neopterin in the cerebrospinal fluid: preferential presence in HTLV type I-infected neurologic patients versus healthy virus carriers. AIDS Res Hum Retroviruses 2000;16:965–972.
20.
Conant K, McArthur JC, Griffin DE, Sjulson L, Wahl LM, Irani DN: Cerebrospinal fluid levels of MMP-2, -7, and -9 are elevated in association with human immunodeficiency virus dementia. Ann Neurol 1999;46:391–398.
21.
Kolb SA, Lahrtz F, Paul R, Leppert D, Nadal D, Pfister HW, Fontana A: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol 1998;84:143–150.
22.
Khuth ST, Akaoka H, Pagenstecher A, Verlaeten O, Belin MF, Giraudon P, Bernard A: Morbillivirus infection of the mouse central nervous system induces region-specific upregulation of MMPs and TIMPs correlated to inflammatory cytokine expression. J Virol 2001;75:8268–8282.
23.
Zhou J, Marten NW, Bergmann CC, Macklin WB, Hinton DR, Stohlman SA: Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. J Virol 2005;79:4764–4773.
24.
Suzuki T, Ogata A, Tashiro K, Nagashima K, Tamura M, Yasui K, Nishihira J: Japanese encephalitis virus up-regulates expression of macrophage migration inhibitory factor (MIF) mRNA in the mouse brain. Biochim Biophys Acta 2000;1517:100–106.
25.
Wakefield TW, Strieter RM, Wilke CA, Kadell AM, Wrobleski SK, Burdick MD, Schmidt R, Kunkel SL, Greenfield LJ: Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:258–268.
26.
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265–275.
27.
Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH, Cho CS: Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 2005;7:R71–R79.
28.
Huang CH, Wong C: Relation of the peripheral multiplication of Japanese B encephalitis virus to the pathogenesis of the infection in the mice. Acta Virol 1963;7:322–330.
29.
Mac Donald F: Murrey valley encephalitis infection in the laboratory mouse. 1. Influence of age on the susceptibility of infection. Aust J Exp Biol Med Sci 1952;30:319–324.
30.
Martínez-Torres FJ, Wagner S, Haas J, Kehm R, Sellner J, Hacke W, Meyding-Lamadé U: Increased presence of matrix metalloproteinases 2 and 9 in short- and long-term experimental herpes simplex virus encephalitis. Neurosci Lett 2004;368:274–278.
31.
Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, Clark-Lewis I, Overall CM, Power C: HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 2003;6:1064–1071.
32.
McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, Clark-Lewis I, Overall CM: Matrix metalloproteinase activity inactivates the cxc chemokine stromal cell-derived factor-1. J Biol Chem 2001;276:43503–43508.
33.
Dean RA: Overall cm proteomics discovery of metalloproteinase substrates in the cellular context by iTRAQ labeling reveals a diverse MMP-2 substrate degradome. Mol Cell Proteomics 2007;6:611–623.
34.
Van den Steen PE, Proost P, Wuyts A, Van Damme J, Opdenakker G: Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO- and leaves RANTES and MCP-2 intact. Blood 2000;96:2673–2681.
35.
Van den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G: Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 2003;270:3739–3749.
36.
McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM: Inflammation dampened by gelatinase a cleavage of monocyte chemoattractant protein-3. Science 2000;289:1202–1206.
37.
Agrawal S, Anderson P, Durbeej M, Van Rooijen N, Ivars F, Opdenakker G, Sorokin LM: Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. Journal Exp Med 2006;203:1007–1019.
38.
Hu J, Van den Steen PE, Sang QX, Opdenakker G: Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007;6:480–498.
39.
Harris JE, Fernandez-Vilaseca M, Elkington PT, Horncastle DE, Graeber MB, Friedland JS: IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J 2007;21:356–365.
40.
Wang P, Dai J, Bai F, Kong KF, Wong SJ, Montgomery RR, Madri JA, Fikrig E: Matrix metalloproteinase 9 facilitates West Nile virus entry into the brain. J Virol 2008;82:8978–8985.
41.
Hartung HP, Kieseier BC: The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 2000;107:140–147.
42.
Nagase H, Woessner JF: Matrix metalloproteinases. J Biol Chem 1999;274:21491–21494.
43.
Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827–839.
44.
Glass WG, Chen BP, Liu MT, Lane TE: Mouse hepatitis virus infection of the central nervous system: chemokine-mediated regulation of host defense and disease. Viral Immunol 2002;15:261–272.
45.
Parra B, Hinton DR, Lin MT, Cua DJ, Stohlman SA: Kinetics of cytokine mRNA expression in the central nervous system following lethal and nonlethal coronavirus-induced acute encephalomyelitis. Virology 1997;233:260–270.
46.
Rempel JD, Murray SJ, Meisner J, Buchmeier MJ: Differential regulation of innate and adaptive immune responses in viral encephalitis. Virology 2004;318:381–392.
47.
Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A: Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon therapy in relapsing and secondary progressive multiple sclerosis patients. Ann Neurol 2001;50:443–451.
48.
Ethell IM, Ethell DW: Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. J Neurosci Res 2007;85:2813–2823.
49.
Chaturvedi UC, Mathur A, Tandon P, Natu SM, Rajvanshi S, Tandon HO: Variable effect on peripheral blood leucocytes during JE virus infection of man. Clin Exp Immunol 1979;38:492–498.
50.
Johnson RT, Burke DS, Elwell M, Leake CJ, Nisalak A, Hoke CH, Lorsomrudee W: Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol 1985;18:567–573.
51.
Mathur A, Khanna N, Chaturvedi UC: Breakdown of blood-brain barrier by virus-induced cytokine during Japanese encephalitis virus infection. Int J Exp Pathol 1992;73:603–611.
52.
Leppert D, Lindberg RL, Kappos L, Leib SL: Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 2001;36:249–257.
53.
Özenci V, Rinaldi L, Teleshova N, Matusevicius D, Kivisäkk P, Kouwenhoven M, Link H: Metalloproteinases and their tissue inhibitors in multiple sclerosis. J Autoimmun 1999;12:297–303.
54.
Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K: Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999;53:1397–1401.
55.
Zhou J, Stohlman SA, Hinton DR, Marten NW: Neutrophils promote mononuclear cell infiltration during viral-induced encephalitis. J Immunol 2003;170:3331–3336.
56.
Rosenberg GA: Matrix metalloproteinases in neuroinflammation. Glia 2002;39:279–291.
57.
Ghoshal A, Das S, Ghosh S, Mishra MK, Sharma V, Koli P, Sen E, Basu A: Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 2007;55:483–496.
58.
Giraudon P, Szymocha R, Buart S, Bernard A, Cartier L, Belin MF, Akaoka H: T lymphocytes activated by persistent viral infection differentially modify the expression of metalloproteinases and their endogenous inhibitors, TIMPs, in human astrocytes: relevance to HTLV-I-induced neurological disease. J Immunol 2000;164:2718–2727.
59.
Giraudon P, Thomasset N, Bernard A, Verrier B, Belin MF: Induction of MMP9 (92 kDa gelatinase) activity and expression of tissue inhibitor of metalloproteinase 2 mRNA (TIMP-2) in primitive neuroectodermal cells infected with retrovirus HTLV-I. Eur J Neurosci 1995;7:841–848.
60.
Maeda A, Sobel RA: Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300–309.
61.
Cossins JA, Clements JM, Ford J, Miller KM, Pigott R, Vos W, Van Der Valk P, De Groot CJ: Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol 1997;94:590–598.
62.
Liuzzi GM, Mastroianni CM, Santacroce MP, Fanelli M, D’Agostino C, Vullo V, Riccio P: Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV-associated neurological diseases. J Neurovirol 2000;6:156–163.
63.
Leib SL, Leppert D, Clements J, Tauber MG: Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infect Immun 2000;68:615–620.
64.
Tung WH, Tsai HW, Lee I: Japanese encephalitis virus induces matrix metalloproteinase-9 in rat brain astrocytes via NF-ĸB signalling dependent on MAPKs and reactive oxygen species. Br J Pharmacol 2010;161:1566–1583.
65.
Mishra MK, Ghosh D, Duseja R, Basu A: Antioxidant potential of minocycline in Japanese encephalitis virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem Int 2009;54:464–470.
66.
Opdenakker G, Van den Steen PE, Van Damme J: Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 2001;22:571–579.
67.
Huang TY, Chu HC, Lin YL, Lin CK, Hsieh TY, Chang WK, Chao YC, Liao CL: Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol Appl Pharmacol 2009;237:69–82.
68.
Elewa HF, Hilali H, Hess DC, Machado LS, Fagan SC: Minocycline for short-term neuroprotection. Pharmacotherapy 2006;26:515–521.
69.
Dutta K, Mishra MK, Nazmi A, Kumawat KL, Basu A: Minocycline differentially modulates macrophage mediated peripheral immune response following Japanese encephalitis virus infection. Immunobiology 2010;215:884–893.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.